The positive short-term impact on ATEC's stock price is due to the company's revenue guidance beating estimates, which is a strong indicator of financial health and often leads to increased investor confidence. The strategic partnership with Aclarion is likely to be viewed as a positive development for future growth prospects, particularly in the commercialization of Nociscan, which could further drive investor interest.